当前位置:首页>产品中心>单抗/多抗>Anti-Human SLC39A7 Polyclonal Antibody|抗人SLC39A7多克隆抗体(靶标:人溶质载体家族39成员7/ZIP7)

Anti-Human SLC39A7 Polyclonal Antibody|抗人SLC39A7多克隆抗体(靶标:人溶质载体家族39成员7/ZIP7)

  • 货号:RB9THD636014
  • 价格:面议
  • 点击:477

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA, IHC, WB
种属反应性Human
靶标HKE4, Histidine-rich membrane protein Ke4, RING5, Really interesting new gene 5 protein, SLC39A7, Solute carrier family 39 member 7, ZIP7, Zinc transporter SLC39A7, Zrt-, Irt-like protein 7
免疫原E. coli - derived recombinant Human SLC39A7 (Gly30-Thr133).
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号Q92504
背景信息

Zinc transporter SLC39A7 is a ~50 kDa protein. Transports Zn(2+) from the endoplasmic reticulum (ER)/Golgi apparatus to the cytosol, playing an essential role in the regulation of cytosolic zinc levels. Acts as a gatekeeper of zinc release from intracellular stores, requiring post-translational activation by phosphorylation, resulting in activation of multiple downstream pathways leading to cell growth and proliferation. Has an essential role in B cell development and is required for proper B cell receptor signaling. Plays an important role in maintaining intestinal epithelial homeostasis and skin dermis development by regulating ER function. Controls cell signaling pathways involved in glucose metabolism in skeletal muscle.

1. Taylor, KM. et al. (2004) The Biochemical journal 377, 131-9. PMID: 14525538
2. Huang, L. et al. (2005) The Journal of biological chemistry 280, 15456-63. PMID: 15705588
3. Nimmanon, T. et al. (2017) Metallomics : integrated biometal science 9, 471-481. PMID: 28205653
4. Woodruff, G. et al. (2018) Molecular pharmacology 94, 1092-1100. PMID: 29980658
5. Taylor, KM. et al. (2012) Science signaling 5, ra11. PMID: 22317921
6. Anzilotti, C. et al. (2019) Nature immunology 20, 350-361. PMID: 30718914
7. Fauster, A. et al. (2019) Cell death and differentiation 26, 1138-1155. PMID: 30237509
备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody |抗依奇珠单抗非中和重组抗体(靶标:依奇珠单抗非中和抗体) 413
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody |抗依奇珠单抗非中和重组抗体(靶标:依奇珠单抗非中和抗体) 406
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody |抗依奇珠单抗非中和重组抗体(靶标:依奇珠单抗非中和抗体) 607
Anti-Ixekizumab Neutralizing Recombinant Antibody |抗依奇珠单抗中和重组抗体(靶标:依奇珠单抗中和抗体) 583
Anti-Ixekizumab Neutralizing Recombinant Antibody |抗依奇珠单抗中和重组抗体(靶标:依奇珠单抗中和抗体) 511
Anti-Ixekizumab Neutralizing Recombinant Antibody |抗依奇珠单抗中和重组抗体(靶标:依奇珠单抗中和抗体) 477
Anti-Daratumumab Non-Neutralizing Recombinant Antibody|抗达雷妥尤单抗非中和重组抗体(靶标:达雷妥尤单抗非中和抗体) 549
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 588
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 536
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 649
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 614
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 329
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 416
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 589
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 417
Anti-Avelumab Neutralizing Recombinant Antibody |抗阿维鲁单抗中和重组抗体(靶标:阿维鲁单抗中和抗体) 609
Anti-Avelumab Neutralizing Recombinant Antibody |抗阿维鲁单抗中和重组抗体(靶标:阿维鲁单抗中和抗体) 412
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 643
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 624
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 566
总计 33037 个记录,共 1652 页,当前第 1648 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00